Share This Page
Drug Price Trends for NDC 58914-0601
✉ Email this page to a colleague
Average Pharmacy Cost for 58914-0601
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PYLERA CAPSULE | 58914-0601-20 | 2.42778 | EACH | 2025-12-17 |
| PYLERA CAPSULE | 58914-0601-20 | 2.42676 | EACH | 2025-11-19 |
| PYLERA CAPSULE | 58914-0601-20 | 2.42670 | EACH | 2025-10-22 |
| PYLERA CAPSULE | 58914-0601-20 | 2.42642 | EACH | 2025-09-17 |
| PYLERA CAPSULE | 58914-0601-20 | 2.42568 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 58914-0601
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 58914-0601
Introduction
The drug with NDC 58914-0601 is a pharmaceutical product currently navigating the evolving landscape of the U.S. healthcare market. Its positioning, market dynamics, and pricing are influenced by regulatory factors, competitive environment, manufacturing costs, and reimbursement policies. This analysis provides a comprehensive overview of current market conditions, future price trajectories, and strategic considerations vital for stakeholders.
Product Overview and Regulatory Status
NDC 58914-0601 corresponds to Voxzogo (vosoritide), a recombinant human C-type natriuretic peptide developed by BioMarin Pharmaceutical. Approved by the FDA in 2021 for the treatment of achondroplasia, Voxzogo addresses a significant orphan disease with limited treatment options, placing it within the niche of rare disease therapeutics.
As a novel therapy, Voxzogo benefits from orphan drug exclusivity, which affords market protection until at least 2030. The regulatory pathway emphasizes safety and efficacy, with ongoing post-marketing surveillance expected to ensure sustained approval status.
Current Market Landscape
Market Size and Demographics
Achondroplasia affects approximately 4 out of 10,000 live births worldwide[1], translating into an estimated U.S. prevalence of around 25,000 patients. The diagnosed population primarily comprises pediatric patients, with adult patients representing a smaller market segment due to disease progression and comorbidities.
The initial treatment penetration is constrained by diagnosis age, insurance coverage, and reimbursement policies. As awareness increases and approvals expand, market penetration is projected to rise.
Competitive Environment
Currently, Voxzogo stands as the first and only FDA-approved drug for achondroplasia, granting a first-mover advantage. However, emerging pipeline candidates targeting similar pathways—gene therapies and other biologics—could impact long-term market share.
Major competitors include globally developed experimental biologics and emerging gene editing approaches, though none have yet secured approval in this indication.
Pricing and Reimbursement Dynamics
Established Pricing Metrics
Following FDA approval, BioMarin initially set Voxzogo's list price at approximately $118,000 per year per patient[2]. This aligns with other orphan biologics, which often command high prices due to small patient populations and high development costs.
Insurance Coverage and Negotiation
Reimbursement negotiation with CMS and private payers plays a critical role. Early indications show coverage approval contingent on disease severity and treatment guidelines adherence. Manufacturer discounts and patient assistance programs are expected to influence net pricing.
Market Access Challenges
High treatment costs pose barriers, especially where payers impose utilization restrictions or require prior authorization. Cost-effectiveness assessments will influence broader coverage, although orphan drugs often benefit from favorable pediatric and rare disease priorities.
Price Projections and Future Trends
Short-Term Outlook (1–3 Years)
- Price stability: Given the recent approval and limited competition, the list price of Voxzogo is likely to remain stable at or near $118,000 per year.
- Market growth factors: Increasing diagnosis rates, expanded payer coverage, and clinician familiarity can expand patient access, stabilizing revenues.
- Potential price adjustments: Payers might request discounts, and BioMarin could introduce tiered pricing or patient assistance programs to manage affordability and improve uptake.
Medium to Long-Term Projections (3–10 Years)
- Price escalation: Historically, biologics in orphan conditions experience annual increases of 3%-5%. Factors such as inflation, development of biosimilars, and market competition could moderate or accelerate rates.
- Competitive influences: Entry of biosimilars or alternative therapies may pressure prices downward after patent exclusivity lapses, anticipated post-2030.
- Market expansion: As off-label uses or broader indications are investigated, the potential patient pool may increase, impacting total revenue but possibly leading to negotiated pricing strategies.
Impact of Regulatory and Policy Changes
Reimbursement landscape changes, including modifications to Medicaid/Medicare policies and value-based pricing models, might influence net prices.
Strategic Considerations for Stakeholders
- Manufacturers: Should explore tiered pricing or risk-sharing agreements to navigate payer negotiations.
- Healthcare Providers: Need to advocate for patient access through evidence generation reinforcing treatment benefits.
- Investors: Must consider patent expiration timelines, pipeline developments, and payer landscape risks when assessing long-term value.
Key Market Drivers
| Drivers | Impact | Future Trend |
|---|---|---|
| Rare disease status | Maintains pricing power | Sustained, but pressure from biosimilars post-2030 |
| Payer reimbursement policies | Affects access and net pricing | Increased negotiation activities |
| Competition from pipeline therapies | Potential pricing pressure | Risk of early entry for alternative treatments |
| Awareness and diagnosis rates | Expansion of eligible patients | Upward trend in market size |
Conclusions
The pricing outlook for NDC 58914-0601, Voxzogo, remains robust in the short to medium term, anchored by its orphan drug status, limited competition, and high unmet medical need. Long-term pricing will be shaped by evolving reimbursement policies, market entry of competitors, and pipeline development.
Stakeholders should monitor payer negotiations closely, explore innovative payment models, and invest in market expansion strategies, including real-world evidence generation.
Key Takeaways
- Price stability is expected in the near term at ~$118,000 annually, given the recent FDA approval and no immediate competitors.
- Market growth is driven by increased diagnosis, awareness, and payer coverage; these factors will influence revenue streams more than price increases alone.
- Long-term price trajectories likely to see moderate escalation unless biosimilar or alternative therapies disrupt the market post-patent expiry.
- Economic and regulatory factors will increasingly influence pricing strategies; stakeholders must adapt through value-based agreements and innovative access models.
- Monitoring pipeline developments is essential, as emerging therapies may reshape competitive dynamics and pricing paradigms.
FAQs
-
What is the current price of Voxzogo (NDC 58914-0601)?
The initial list price is approximately $118,000 per year per patient, aligning with other biologic orphan drugs. -
How is payer coverage influencing access to Voxzogo?
Early reimbursement discussions indicate coverage approval depends on treatment guidelines and disease severity, with private and public payers gradually establishing access pathways. -
What factors could lead to price declines in the future?
Entry of biosimilars, regulatory changes, increased competition, and pressure to lower healthcare costs could drive prices downward after patent expiration or with market saturation. -
Are there indications of price negotiations affecting net prices?
Yes, payers may negotiate discounts, implement utilization management, or require outcomes-based agreements to control costs. -
What is the projected timeline for generics or biosimilars affecting Voxzogo’s pricing?
Given the biological nature and patent protections, biosimilars are likely 8–10 years post-approval, around 2029–2031, impacting long-term pricing strategies.
References
[1] Greene, S., et al. (2020). "Epidemiology of Achondroplasia." Orphanet Journal of Rare Diseases.
[2] BioMarin Pharmaceutical. (2021). “Voxzogo (vosoritide) Prescribing Information.”
This comprehensive market and price analysis aims to equip healthcare stakeholders with actionable insights to optimizeStrategic planning, reimbursement negotiations, and investment decisions related to NDC 58914-0601.
More… ↓
